NexImmune, Inc. (NEXI)
| Market Cap | 379.63K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.62M |
| Shares Out | 1.39M |
| EPS (ttm) | -17.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,500 |
| Open | 0.252 |
| Previous Close | 0.232 |
| Day's Range | 0.232 - 0.274 |
| 52-Week Range | 0.200 - 28.700 |
| Beta | 1.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 7, 2025 |
About NexImmune
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologo... [Read more]
Financial Performance
Financial StatementsNews
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...
Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping
Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by mo...
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune...
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...
NexImmune Announces 1-for-25 Reverse Stock Split
GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targe...
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy
GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates
GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 tre...
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates
GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune respo...
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune res...
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
GAITHERSBURG, Md., March 28, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune res...
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
GAITHERSBURG, Md., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...
NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company's AIM Platform to Treat Viral Diseases
GAITHERSBURG, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...
NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update
GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...
NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)
The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunologic...
NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targ...
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell i...
NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers
GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targe...
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targe...
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune's AIM nanoparticles in combination with ...
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targ...